Journal of the American Academy of Child & Adolescent Psychiatry
ArticlesCase Series: Use of Ziprasidone for Maladaptive Symptoms in Youths With Autism
Section snippets
Subjects
This study was approved by the Institutional Review Board of Indiana University. The diagnoses, demographic information, treatment history with antipsychotic drugs, and rationale for ziprasidone administration are presented in Table 1. The sample included 12 patients (2 females, 10 males) (mean age, 11.62 ± 4.38 years; range, 8–20 years), including nine with autistic disorder and three with PDD NOS. All diagnoses were made by two board-certified child and adolescent psychiatrists during a
RESULTS
The final mean daily dose of ziprasidone was 59.23 ± 34.76 mg (range, 20–120 mg). All of the patients completed at least 6 weeks of treatment with ziprasidone (mean duration, 14.15 ± 8.29 weeks; range, 6–30 weeks). Six (50%) of the 12 patients were considered responders to treatment. Two were rated as “much worse.” Both of these patients had comorbid bipolar I disorder. Five of the six responders continued to take ziprasidone at the end of the trial. The sixth patient was asked to discontinue
DISCUSSION
This report describes our initial clinical impressions and experience with regard to the first 12 patients with autism or PDD NOS whom we treated with ziprasidone. Although the sample size is small, the overall rate of response is similar to prior reports of treatment with risperidone (McDougle et al., 1998) and olanzapine (Malone et al., 2001;Potenza et al., 1999) in subjects with autism and other PDDs. Unlike earlier studies involving children and adolescents with autism, the patients in the
REFERENCES (36)
- et al.
Radioreceptor binding profile of the atypical antipsychotic olanzapine
Neuropsychopharmacology
(1996) - et al.
A comparison of haloperidol and behavior therapy and their interaction in autistic children
J Am Acad Child Psychiatry
(1978) - et al.
Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial
Neuropsychopharmacology
(1999) - et al.
The relationship between repetitive behaviors and growth hormone response to sumatriptan challenge in adult autistic disorder
Neuropsychopharmacology
(2000) - et al.
Olanzapine versus haloperidol in children with autistic disorder: an open pilot study
J Am Acad Child Adolesc Psychiatry
(2001) - et al.
Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study
J Am Acad Child Adolesc Psychiatry
(1997) - et al.
Background and rationale for an initial controlled study of risperidone
Child Adolesc Psychiatr Clin North Am
(2000) - et al.
Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study
J Am Acad Child Adolesc Psychiatry
(2000) Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV)
(1994)- et al.
Assessment in multisite randomized clinical trials of patients with autistic disorder: the autism RUPP network
J Autism Dev Disord
(2000)
Clozapine: a novel antipsychotic agent
N Engl J Med
Local cerebral glucose metabolic rates in obsessive-compulsive disorder: a comparison with rates in unipolar depression and in normal controls
Arch Gen Psychiatry
Clozapine in the treatment of aggression in an adolescent with autistic disorder
J Clin Psychiatry
Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics
J Clin Psychiatry
Use of risperidone in pervasive developmental disorders: a case series
J Child Adolesc Psychopharmacol
Ziprasidone in the acute treatment of mania: a double-blind, placebo-controlled, randomized trial
Schizophr Res
ECDEU Assessment Manual for Psychopharmacology (NIMH Publication 76–338)
Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism
J Child Adolesc Psychopharmacol
Cited by (132)
The pediatric psychopharmacology of autism spectrum disorder: A systematic review - Part I: The past and the present
2021, Progress in Neuro-Psychopharmacology and Biological PsychiatryCitation Excerpt :A retrospective chart review involving 42 ASD patients yielded 40% response rates on irritability (Dominick et al., 2015). The drug was relatively safe, with side effects including transient sedation, mean QTc increase of 14.7 msec and acute dystonic reactions in 2 subjects (McDougle et al., 2002; Malone et al., 2007; Dominick et al., 2015). Paliperidone acts primarily as an antagonist at dopamine D2, serotonin 5-HT2, and noradrenergic α2 receptors.
Psychopharmacology of Treating Explosive Behavior
2021, Child and Adolescent Psychiatric Clinics of North AmericaThe psychopharmacology of autism spectrum disorder and Rett syndrome
2019, Handbook of Clinical NeurologyAutism Spectrum Disorder: Classification, diagnosis and therapy
2018, Pharmacology and TherapeuticsCitation Excerpt :One study reported significant improvement in aggression, agitation, and irritability after 14 weeks of treatment with ziprasidone (mean dose 59 mg/d). The drug was well tolerated, and a few patients even lost weight (average weight lost 5.8 lb), which may be attributable to switching from other atypical agents that are commonly associated with significant weight gain (McDougle, Kem, & Posey, 2002). Another study assessed the effects of switching 10 adult ASD patients, who had suffered excessive weight gain while on risperidone or quetiapine, to ziprasidone.
Treating aggression in persons with autism spectrum disorders: A review
2014, Research in Developmental DisabilitiesCitation Excerpt :Thirteen of the papers reported on the treatment of one or two individuals (Braithwaite & Richdale, 2000; Davis et al., 2013; Falcomata, Roane, Muething, Stephenson, & Ing, 2012; Fisher, Lindauer, Alterson, & Thompson, 1998; Foxx & Garito, 2007; Foxx & Meindl, 2007; Hittner, 1994; Kern, Carberry, & Haidara, 1997; Kuhn, Hardesty, & Sweeney, 2009; Luiselli, Blew, Keane, Thibadeau, & Holzman, 2000; Matson, LoVullo, Boisjoli, & Gonzales, 2008; Robertson, Wehby, & King, 2013; Sigafoos & Meikle, 1996), and two studies involved 100 or more people (Marcus et al., 2009; Silverman et al., 2014). The higher number of participated studies involved drug treatments (Arnold et al., 2003; Hellings et al., 2005; King & Davanzo, 1996; Marcus et al., 2009; McDougle et al., 1996; McDougle, Kem, & Posey, 2002; McDougle et al., 1998; Owen et al., 2009; Silverman et al., 2014; Troost et al., 2005), while the low number studies were largely psychologically based interventions. Again, this makes sense in that drug interventions for aggression are far less time intensive than psychologically based treatments.
Characteristics of aggression among persons with autism spectrum disorders
2014, Research in Autism Spectrum Disorders
This work was supported in part by a Young Investigator Award from the National Alliance for Research in Schizophrenia and Depression (Dr. Posey), a Daniel X. Freedman Psychiatric Research Fellowship Award (Dr. Posey), Department of Housing and Urban Development grant B-01-SP-IN-0200 ( Representative Dan Burton), and a Research Unit on Pediatric Psychopharmacology Contract ( NO1MH70001 ) from the NIMH to Indiana University (Drs. McDougle and Posey and Ms. Kem).
Reprint requests to Dr. McDougle, Indiana University School of Medicine, Department of Psychiatry, Krannert Building, Room A305, 1111 W. 10th Street, Indianapolis, IN 46202-4800.